Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-19. (Canceled)

20. (Currently amended) A composition in the form of a free flowing, compressible powder, ~~consisting~~ comprising (i) porous powders or a mixture of porous powders, and (ii) water-insoluble or poorly soluble compounds that dissolve in melted lipids and are absorbed by the porous powders or the mixture of porous powders, wherein the lipids are GELUCIRE or vitamin E TPGS ~~particles and solid lipids that are absorbed in the pores of the particles in melting state~~.

21-22. (Canceled)

23. (Currently amended) The composition of claim 20 wherein the ~~comprising, at least, a~~ compound that dissolves in the melted lipids and forms solutions, micelles, microemulsion, or emulsion with the lipids in an aqueous medium.

24. (Currently amended) The composition of claim 20 wherein the ~~said~~ composition facilitates formation of solutions, micelles, microemulsions or emulsions of poorly soluble or water insoluble compounds ~~and the lipids after administration~~ with no need of pre-emulsification of the compounds during formulation.

25-27. (Canceled)

28. (Currently amended) The composition of claim 20 ~~27~~, wherein the porous powders or the mixture of porous powders have specific surface area ~~is~~ larger than 100 m^2/g.

29. (Currently amended) The composition of claim 20 ~~27~~, wherein the porous powders or the mixture of porous powders have ~~pore structure has~~ a diameter less than 50 nm.

30. (Currently amended) The composition of claim 20 ~~29~~, wherein the porous powders are ~~pore structure is~~ alumina, silica or their mixture.

31. (Currently amended) The composition of claim 20 ~~23~~, wherein the compound is cyclosporine, triamterene ~~triamteren~~, acyclovir, doxorubicin, labetalol, doxepin, methyldopa or pentoxifyll.

32. (Previously presented) A pharmaceutical composition comprising the composition of claim 20 and a pharmaceutically acceptable carrier.

33. (Withdrawn) A method for producing the compositions of claim 21 comprising steps of:

a) melting the said solid lipid or lipid mixture by heating;

b) dissolving the said compound in melted lipid or lipid mixtures;

c) impregnating the said porous powders with the drug-lipid melt; and

d) cooling the porous powder impregnated with the drug-lipid melt to room temperature to solidify the drug-lipid melt.

34. (Withdrawn) The method of claim 33, further comprising granulation, capsule filling, tableting, coating and paste making of the produced composition.

35-36. (Canceled)

37. (Currently amended) The composition of claim 20 ~~35~~, formulated in powders, capsules, granules, coated granules, tablets or coated tablets.

38. (Currently amended) The formulated composition of claim 37, comprising ~~the~~ excipients selected from the group consisting of ~~containing~~ binders, diluents, disintegrants, coating material, and lubricants.